Thoma Bravo has made a strategic growth investment in Bluesight, which works to help with supply chain inefficiencies and reduce risk through the use of AI and machine learning for analytics.
Bluesight aims to transform the hospital pharmacy supply chain through software. The investment looks to improve Bluesight’s drug diversion prevention offerings through its acquisition of Medacist, a drug diversion monitoring company, and continue to grow Bluesight’s inventory management spend optimization offerings. Current investor New Leaf Ventures will remain invested in the business.
“The combination of Bluesight and Medacist capitalizes on the growing demand for software solutions that transform how health system pharmacies manage medication inventory and compliance,” says Carl Press, a partner at Thoma Bravo.